ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

28.90

+0.54 (1.90%)

Sep 18, 2026, 4:00 PM EDT - Market closed

ArriVent BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	31.64	24.18	15.3	9.71	6.47	3.02
Research & Development	144.3	153.35	79	64.88	30.43	8.58
Operating Expenses	175.94	177.53	94.31	74.59	36.91	11.59
Operating Income	-175.94	-177.53	-94.31	-74.59	-36.91	-11.59
Interest & Investment Income	12.21	11.23	13.82	5.26	-	-
EBT Excluding Unusual Items	-163.74	-166.31	-80.49	-69.33	-36.91	-11.59
Pretax Income	-164.21	-166.31	-80.49	-69.33	-36.91	-68.81
Net Income	-164.21	-166.31	-80.49	-69.33	-36.91	-68.81
Net Income to Common	-164.21	-166.31	-80.49	-69.33	-36.91	-68.81
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	44	38	31	2	1	1
Shares Outstanding (Diluted)	44	38	31	2	1	1
Shares Change	30.39%	22.22%	1369.88%	67.64%	79.57%	-
EPS (Basic)	-3.70	-4.32	-2.56	-32.38	-28.90	-96.75
EPS (Diluted)	-3.70	-4.32	-2.56	-32.38	-28.90	-96.75
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EBIT	-175.94	-177.53	-94.31	-74.59	-36.91	-11.59

SEC Filings: 10-K · 10-Q